Landmark Shift in Bone Marrow Transplants: Cyclophosphamide revolutionizes care, offers Hope for More Patients
Table of Contents
A new era in bone marrow transplantation is underway, marked by a dramatic reduction in life-threatening complications and a broadening of eligibility for patients, thanks to the widespread adoption of post-transplant cyclophosphamide.
For 50 years, the Fred Hutchinson Cancer Center has been at the forefront of bone marrow transplantation (BMT), a treatment that began as a daring frontier in oncology and has now saved over 1.5 million lives worldwide. The journey from a high-risk, often fatal procedure to a more manageable and effective therapy has been defined by relentless research and, more recently, the game-changing introduction of post-transplant cyclophosphamide.
From 40% Mortality to a New Standard of Care
In the early days of BMT, the potential for cure was frequently enough overshadowed by meaningful risks. “Despite the fact that BMT coudl cure cancer, we still lost 30 to 40% of people from transplant-related mortality, mainly graft-vs.-host disease and infection,” recalls a senior researcher with decades of experience in the field.
“With post-transplant cyclophosphamide, you don’t use the same immune-suppressive regimen when you do the stem cell transplant,” explains a leading transplant physician. “historically, we’d start the immunosuppression two or three days before the graft.Now, we do nothing.” This allows a robust immune response to occur, followed by a targeted dose of cyclophosphamide on day three or four, which preferentially kills the T cells reacting against the recipient’s tissues.
Unlike earlier attempts to prevent GVHD by removing all T cells – a strategy that led to overwhelming infections and relapse – cyclophosphamide strikes a crucial balance. “We don’t see higher rates of relapse with post-transplant cyclophosphamide, even though early infection is an issue in many studies,” notes one researcher.
Expanding Access and Improving Outcomes
Post-transplant cyclophosphamide has been successfully implemented in almost all transplant settings, excluding cord blood transplants, where the low stem cell count presents a separate challenge. The approach, initially pioneered at Johns Hopkins and refined by researchers at Fred Hutch, is notable for its affordability and accessibility. “It’s cheap and anyone anywhere in the world can do it,” states a senior official. “And it’s so effective, it’s really a worldwide standard of care now, at least in North America.”
Recent studies have demonstrated the efficacy of cyclophosphamide in various scenarios. Research led by Brenda Sandmaier and Masumi Oshima showed dramatically reduced rates of chronic GVHD when compared to traditional immunosuppression regimens. A major study by the Center for International Blood and Marrow Transplant Research (CIBMTR) confirmed these findings, demonstrating similar improvements with cyclophosphamide in unrelated donor transplants.
the Future of BMT: Relapse Prevention and Expanding Eligibility
While the reduction in GVHD is a monumental achievement, researchers are now focused on preventing relapse, which has become the primary cause of treatment failure.”What we don’t understand now, which is super captivating, is why – despite profound reductions in GVHD – we aren’t seeing increased rates of relapse,” explains a leading researcher.
Current research is exploring strategies to enhance the anti-leukemic affect of cyclophosphamide, including the use of specific cytokines and growth factors. There’s also a growing movement to expand transplant eligibility to older patients,even those with residual disease. As Fred and Jake Appelbaum recently argued, “in life, as in sports… put your best player on the field.” And for many patients with blood cancers, that “best player” is a bone marrow transplant.
The ongoing quest to refine BMT and make it accessible to a wider population underscores the enduring legacy of the Fred Hutchinson Cancer Center and its commitment to pushing the boundaries of cancer treatment.
